Sulindac sulfone
Based on 1 Customer Validation
Sulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of VDAC1/2 to inhibit the mTORC1 pathway, reduces Cyclin D1 levels, and induces G1 cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer.
For research use only. We do not sell to patients.
- Purity : 98.10%
- CAS No.: 59973-80-7
- Formula: C20H17FO4S
- Molecular Weight:372.41
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
mTORC1 |
PPARγ |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COLO 320 | IC50 |
>200 μM
Compound: b
|
Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay
Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay
|
[PMID: 20801552] |
| MIA PaCa-2 | IC50 |
>200 μM
Compound: b
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay
|
[PMID: 20801552] |
In Vitro
Sulindac sulfone (50-600 μM; 1-6 days) inhibits the proliferation and induces the death of colon cancer cell line Caco-2. After 6 days of treatment, the inhibitory effect on proliferation at concentrations ≥50 μM and the inducing effect on cell death at concentrations ≥150 μM are both statistically significant[1].
Sulindac sulfone (600 μM; duration leading to 50% reduction in colony formation) upregulates the expression of the SSAT gene by 3.94-fold in the colon cancer cell line Caco-2 at its IC50 concentration[1].
Sulindac sulfone (10-600 μM; 24-48 h) induces the expression of SSAT mRNA in the colon cancer cell line Caco-2; at the concentration of 600 μM, the expression level increases by 2.23-fold after 24 h of treatment and by 5.58-fold after 48 h of treatment; statistically significant induction is also observed at concentrations ≥100 μM with 48 h of treatment[1].
Sulindac sulfone (600 μM; 48 h) increases SSAT enzyme activity by 2-fold and reduces intracellular spermine and spermidine levels by 2-fold in human colon cancer Caco-2 cells[1].
Sulindac sulfone (600 μM; 48 h) activates PPAR response elements and increases luciferase activity by 2-fold in Caco-2 colon cancer cells after 48 h of treatment[1].
Sulindac sulfone (up to 10 mM) does not inhibit cyclooxygenase (type I) activity[2].
Sulindac sulfone (1-100 μM) weakly inhibits 5-lipoxygenase activity, with inhibition rates of 10%, 14% and 30% at concentrations of 1 μM, 10 μM and 100 μM, respectively[2].
Sulindac sulfone (1-100 μM) exerts no significant inhibitory effect on 15-lipoxygenase activity: the inhibition rate is 8% at 1 μM, 0% at 10 μM, while the enzyme activity increases by 15% instead at 100 μM[2].
Sulindac sulfone (9.4-600 μM; 72 h) inhibits the growth of colon cancer HT-29, DLD-1 and SW480 cells in a dose-dependent manner. A significant reduction in cell viability is observed at concentrations ≥37.5 μM after 72 h of treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Colon cancer HT-29, DLD-1, and SW480 cells
-
Concentration:9.4, 18.8, 37.5, 75, 150, 300, 600 μM
-
Incubation Time:72 h
-
Result:Inhibited cell growth in all three cell lines in a dose-dependent manner.
Reduced cell viability to ~10-20% at 600 μM across all cell lines.
Caused statistically significant decreases in cell viability at ≥37.5 μM (HT-29), ≥150 μM (DLD-1), and ≥150 μM (SW480).
-
Cell Line:Colon cancer HT-29, DLD-1, and SW480 cells
-
Concentration:75, 150, 300, 600 μM
-
Incubation Time:72 h
-
Result:Induced G1 phase cell cycle arrest in all three cell lines.
Caused statistically significant increases in G1 phase population at all tested concentrations.
Caused statistically significant decreases in S phase population at 300 and 600 μM across all cell lines.
-
Cell Line:human colon cancer HT-29, DLD-1, and SW480 cells
-
Concentration:600 μM
-
Incubation Time:24 h
-
Result:Did not reduce the expression levels of VDAC1 or VDAC2 in any of the three cell lines.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:F344 (male, 6 weeks old at study start, azoxymethane-induced colon cancer model)[2]
-
Dosage:500 ppm; 1000 ppm; 2000 ppm
-
Administration:dietary; continuous; 31 weeks
-
Result:Achieved mean serum levels of 92 μg/mL (500 ppm), 129 μg/mL (1000 ppm), and 146 μg/mL (2000 ppm), and mean cecal levels of 0.96 mg/mL (500 ppm), 1.24 mg/mL (1000 ppm), and 2.59 mg/mL (2000 ppm), with no metabolic conversion to sulindac or other metabolites detected.
Reduced carcinoma burden to 3.53 cm at 500 ppm (P < 0.05 vs control).
Lowered colon adenoma incidence to 40.0%, carcinoma incidence to 36.7%, and overall neoplasia incidence to 63.3% at 1000 ppm (all P < 0.05 vs control).
Reduced tumor multiplicity to 0.53 adenomas/animal, 0.37 carcinomas/animal, and 0.90 total neoplasia/animal at 1000 ppm (all P < 0.05 vs control).
Lowered tumor burden to 1.50 cm for adenomas, 1.77 cm for carcinomas, and 3.27 cm for total neoplasia at 1000 ppm (all P < 0.05 vs control).
Reduced colon adenoma incidence to 20.0%, carcinoma incidence to 10.0%, and overall neoplasia incidence to 26.7% at 2000 ppm (all P < 0.05 vs control).
Lowered tumor multiplicity to 0.30 adenomas/animal, 0.13 carcinomas/animal, and 0.43 total neoplasia/animal at 2000 ppm (all P < 0.05 vs control).
Reduced tumor burden to 0.70 cm for adenomas, 1.17 cm for carcinomas, and 1.87 cm for total neoplasia at 2000 ppm (all P < 0.05 vs control).
Exhibited a highly significant dose-response relationship for colon tumor incidence (P < 0.0001), multiplicity (P < 0.0001), and burden (P = 0.0001).
Maintained colonic PGE2 levels at 78-118% of control levels across all doses, with no statistically significant reduction detected in either proximal or distal colon.
Chemical Information
-
CAS No. 59973-80-7
-
Appearance Solid
-
Molecular Weight 372.41
-
Formula C20H17FO4S
-
Color Light yellow to yellow
-
SMILES
O=C(O)CC(C1=C/2C=CC(F)=C1)=C(C)C2=C\C3=CC=C(S(=O)(C)=O)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (335.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Babbar N, et al. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003;278(48):47762-47775. [Content Brief]
[2]. Piazza GA, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997 Jul 15;57(14):2909-15. [Content Brief]
[3]. Aono Y, et al. Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2. Biochem Biophys Res Commun. 2018;505(4):1203-1210. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6852 mL | 13.4261 mL | 26.8521 mL | 67.1303 mL |
| 5 mM | 0.5370 mL | 2.6852 mL | 5.3704 mL | 13.4261 mL | |
| 10 mM | 0.2685 mL | 1.3426 mL | 2.6852 mL | 6.7130 mL | |
| 15 mM | 0.1790 mL | 0.8951 mL | 1.7901 mL | 4.4754 mL | |
| 20 mM | 0.1343 mL | 0.6713 mL | 1.3426 mL | 3.3565 mL | |
| 25 mM | 0.1074 mL | 0.5370 mL | 1.0741 mL | 2.6852 mL | |
| 30 mM | 0.0895 mL | 0.4475 mL | 0.8951 mL | 2.2377 mL | |
| 40 mM | 0.0671 mL | 0.3357 mL | 0.6713 mL | 1.6783 mL | |
| 50 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3426 mL | |
| 60 mM | 0.0448 mL | 0.2238 mL | 0.4475 mL | 1.1188 mL | |
| 80 mM | 0.0336 mL | 0.1678 mL | 0.3357 mL | 0.8391 mL | |
| 100 mM | 0.0269 mL | 0.1343 mL | 0.2685 mL | 0.6713 mL |